The 2003 Nicolas Andry award: Orthopaedic gene therapy

Christopher H Evans, Steven C. Ghivizzani, Paul D. Robbins

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

We review progress in the field of orthopaedic gene therapy since the concept of using gene transfer to address orthopaedic problems was initiated approximately 15 years ago. The original target, arthritis, has been the subject of two successful Phase I clinical trials, and additional human studies are pending in rheumatoid arthritis and osteoarthritis. The repair of damaged musculoskeletal tissues also has proved to be a fruitful area of research, and impressive enhancement of bone healing has been achieved in preclinical models. Rapid progress also is being made in the use of gene transfer to improve cartilage repair, ligament healing, and restoration of various additional tissues, including tendon and meniscus. Other applications include intervertebral disc degeneration, aseptic loosening, osteoporosis, genetic diseases, and orthopaedic tumors. Of these various orthopaedic targets of gene therapy, tissue repair is likely to make the earliest clinical impact because it can be achieved with existing technology. Tissue repair may become one of the earliest clinical successes for gene therapy as a whole. Orthopaedics promises to be a leading discipline for the use of human gene therapy.

Original languageEnglish (US)
Pages (from-to)316-329
Number of pages14
JournalClinical Orthopaedics and Related Research
Issue number429
DOIs
StatePublished - Dec 2004
Externally publishedYes

Fingerprint

Genetic Therapy
Orthopedics
Intervertebral Disc Degeneration
Clinical Trials, Phase I
Inborn Genetic Diseases
Ligaments
Osteoarthritis
Tendons
Genes
Osteoporosis
Arthritis
Cartilage
Rheumatoid Arthritis
Technology
Bone and Bones
Research
Neoplasms

ASJC Scopus subject areas

  • Surgery
  • Orthopedics and Sports Medicine

Cite this

The 2003 Nicolas Andry award : Orthopaedic gene therapy. / Evans, Christopher H; Ghivizzani, Steven C.; Robbins, Paul D.

In: Clinical Orthopaedics and Related Research, No. 429, 12.2004, p. 316-329.

Research output: Contribution to journalArticle

Evans, Christopher H ; Ghivizzani, Steven C. ; Robbins, Paul D. / The 2003 Nicolas Andry award : Orthopaedic gene therapy. In: Clinical Orthopaedics and Related Research. 2004 ; No. 429. pp. 316-329.
@article{7041d9ff6f794e1fb2b2377160b5e920,
title = "The 2003 Nicolas Andry award: Orthopaedic gene therapy",
abstract = "We review progress in the field of orthopaedic gene therapy since the concept of using gene transfer to address orthopaedic problems was initiated approximately 15 years ago. The original target, arthritis, has been the subject of two successful Phase I clinical trials, and additional human studies are pending in rheumatoid arthritis and osteoarthritis. The repair of damaged musculoskeletal tissues also has proved to be a fruitful area of research, and impressive enhancement of bone healing has been achieved in preclinical models. Rapid progress also is being made in the use of gene transfer to improve cartilage repair, ligament healing, and restoration of various additional tissues, including tendon and meniscus. Other applications include intervertebral disc degeneration, aseptic loosening, osteoporosis, genetic diseases, and orthopaedic tumors. Of these various orthopaedic targets of gene therapy, tissue repair is likely to make the earliest clinical impact because it can be achieved with existing technology. Tissue repair may become one of the earliest clinical successes for gene therapy as a whole. Orthopaedics promises to be a leading discipline for the use of human gene therapy.",
author = "Evans, {Christopher H} and Ghivizzani, {Steven C.} and Robbins, {Paul D.}",
year = "2004",
month = "12",
doi = "10.1097/01.blo.0000148854.14399.ec",
language = "English (US)",
pages = "316--329",
journal = "Clinical Orthopaedics and Related Research",
issn = "0009-921X",
publisher = "Springer New York",
number = "429",

}

TY - JOUR

T1 - The 2003 Nicolas Andry award

T2 - Orthopaedic gene therapy

AU - Evans, Christopher H

AU - Ghivizzani, Steven C.

AU - Robbins, Paul D.

PY - 2004/12

Y1 - 2004/12

N2 - We review progress in the field of orthopaedic gene therapy since the concept of using gene transfer to address orthopaedic problems was initiated approximately 15 years ago. The original target, arthritis, has been the subject of two successful Phase I clinical trials, and additional human studies are pending in rheumatoid arthritis and osteoarthritis. The repair of damaged musculoskeletal tissues also has proved to be a fruitful area of research, and impressive enhancement of bone healing has been achieved in preclinical models. Rapid progress also is being made in the use of gene transfer to improve cartilage repair, ligament healing, and restoration of various additional tissues, including tendon and meniscus. Other applications include intervertebral disc degeneration, aseptic loosening, osteoporosis, genetic diseases, and orthopaedic tumors. Of these various orthopaedic targets of gene therapy, tissue repair is likely to make the earliest clinical impact because it can be achieved with existing technology. Tissue repair may become one of the earliest clinical successes for gene therapy as a whole. Orthopaedics promises to be a leading discipline for the use of human gene therapy.

AB - We review progress in the field of orthopaedic gene therapy since the concept of using gene transfer to address orthopaedic problems was initiated approximately 15 years ago. The original target, arthritis, has been the subject of two successful Phase I clinical trials, and additional human studies are pending in rheumatoid arthritis and osteoarthritis. The repair of damaged musculoskeletal tissues also has proved to be a fruitful area of research, and impressive enhancement of bone healing has been achieved in preclinical models. Rapid progress also is being made in the use of gene transfer to improve cartilage repair, ligament healing, and restoration of various additional tissues, including tendon and meniscus. Other applications include intervertebral disc degeneration, aseptic loosening, osteoporosis, genetic diseases, and orthopaedic tumors. Of these various orthopaedic targets of gene therapy, tissue repair is likely to make the earliest clinical impact because it can be achieved with existing technology. Tissue repair may become one of the earliest clinical successes for gene therapy as a whole. Orthopaedics promises to be a leading discipline for the use of human gene therapy.

UR - http://www.scopus.com/inward/record.url?scp=9644303031&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9644303031&partnerID=8YFLogxK

U2 - 10.1097/01.blo.0000148854.14399.ec

DO - 10.1097/01.blo.0000148854.14399.ec

M3 - Article

C2 - 15577504

AN - SCOPUS:9644303031

SP - 316

EP - 329

JO - Clinical Orthopaedics and Related Research

JF - Clinical Orthopaedics and Related Research

SN - 0009-921X

IS - 429

ER -